- Home
- NVAWW vs WGSWW Comparison
NVAWW vs WGSWW Comparison
Compare NVAWW & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVAWW | WGSWW |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | Australia | United States |
| Employees | N/A | 1000 |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NVAWW | WGSWW |
|---|---|---|
| Price | $35.85 | $0.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.1K | ★ 39.2K |
| Earning Date | 03-02-2025 | 02-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $305,450,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 50.79 |
| 52 Week Low | $3.13 | $0.01 |
| 52 Week High | $67.84 | $0.31 |
Technical Indicators
Market Signals| Indicator | NVAWW | WGSWW |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 29.95 |
| Support Level | $34.76 | N/A |
| Resistance Level | $40.80 | $0.02 |
| Average True Range (ATR) | 2.40 | 0.00 |
| MACD | -0.93 | 0.00 |
| Stochastic Oscillator | 26.23 | 22.01 |
Price Performance
Historical ComparisonAbout NVAWW Nova Minerals Limited Warrant
Nova Minerals Ltd is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project. It includes projects such as Estelle Gold and Critical Minerals Project, RPM, Korbel, Train and Stoney. It operates in one segment which is exploration of minerals and two geographical areas, being Australia and United States, where Australia derives maximum revenue.
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.